Welcome to our book review site go-pdf.online!

You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.

Sign up

Research Awards Index
  • Language: en
  • Pages: 798

Research Awards Index

  • Type: Book
  • -
  • Published: 1986
  • -
  • Publisher: Unknown

None

Journal of the National Cancer Institute
  • Language: en
  • Pages: 430

Journal of the National Cancer Institute

  • Type: Book
  • -
  • Published: 1999-11
  • -
  • Publisher: Unknown

None

Novel Approaches to Selective Treatments of Human Solid Tumors
  • Language: en
  • Pages: 306

Novel Approaches to Selective Treatments of Human Solid Tumors

None

Pleiotropic Action of Selenium in the Prevention and Treatment of Cancer, and Related Diseases
  • Language: en
  • Pages: 166

Pleiotropic Action of Selenium in the Prevention and Treatment of Cancer, and Related Diseases

  • Type: Book
  • -
  • Published: 2019-03-26
  • -
  • Publisher: MDPI

Gene cloning and sequence has provided the opportunity to identify and characterize the functional role of biomarkers expressed in and on tumor cells and the surrounding microenvironment. Molecular and immunologic heterogeneity of cells in the tumor microenvironment contributes to instability, enhanced angiogenesis, and drug resistance of the tumor cell. Since tumor cells are the ultimate therapeutic targets for drugs and therapy development, the tumor microenvironment that regulates the growth and the delivery of effective drug concentrations to tumor cells is the gatekeeper. Thus, to have a significant impact on the overall survival and cure of patients with advanced cancer, the stabilizat...

Cancer Treatment Reports
  • Language: en
  • Pages: 100

Cancer Treatment Reports

  • Type: Book
  • -
  • Published: 1983
  • -
  • Publisher: Unknown

None

Fluoropyrimidines in Cancer Therapy
  • Language: en
  • Pages: 331

Fluoropyrimidines in Cancer Therapy

Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.

NCI Monographs
  • Language: en
  • Pages: 436

NCI Monographs

  • Type: Book
  • -
  • Published: 1987
  • -
  • Publisher: Unknown

None

Development of Folates and Folic Acid Antagonists in Cancer Chemotherapy
  • Language: en
  • Pages: 260

Development of Folates and Folic Acid Antagonists in Cancer Chemotherapy

  • Type: Book
  • -
  • Published: 1987
  • -
  • Publisher: Unknown

None

Handbook of Cancer Vaccines
  • Language: en
  • Pages: 585

Handbook of Cancer Vaccines

An authoritative survey of the scientific background for therapeutic cancer vaccines, the challenges to their development, and their current uses in treating cancer. The authors examine the basic issues that effect all vaccines (such as immune adjuvants and prime-boost strategies), describe the methods for antigen discovery, and review the preclinical development phases for each major vaccine strategy. They also spell out the clinical results for cancer vaccines now beginning to be used in the treatment of many common cancers.

Deoxynucleoside Analogs in Cancer Therapy
  • Language: en
  • Pages: 482

Deoxynucleoside Analogs in Cancer Therapy

Successful cancer chemotherapy relies heavily on the application of various deoxynucleoside analogs. Since the very beginning of modern cancer chemotherapy, a number of antimetabolites have been introduced into the clinic and subsequently applied widely for the treatment of many malignancies, both solid tumors and hematological disorders. In the latter diseases, cytarabine has been the mainstay of treatment of acute myeloid leukemia. Although many novel compounds were synthesized in the 1980s and 1990s, no real improvement was made. However, novel technology is now capable of elucidating the molecular basis of several inborn errors as well as some specific malignancies. This has enabled the ...